Compare Inovio Pharmaceuticals Inc (INO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

PALL trades at $24.85, down 1.04% over 24 hours. Technical indicators show a bullish trend with moving averages supporting a buy signal, though the RSI suggests potential overbought conditions. The stock underwent a 1:5 split effective May 18, 2026. Recent financial ratios are unavailable, limiting fundamental assessment. News sentiment highlights palladium's price weakness as a potential buying opportunity amid supply risks and industrial demand.

Outlook: PALL presents a speculative opportunity tied to palladium's recovery, with technical strength but limited fundamental data. Risks include commodity price volatility and macroeconomic factors. Investors should weigh the bullish technicals against the absence of current financial metrics and exposure to precious metal market fluctuations.